查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细菌性阴道炎药物市场规模及预测 2021 - 2031 年，全球及地区份额、趋势及成长机会分析报告范围：按类型、给药途径、剂型、配销通路和地理划分
市场调查报告书
商品编码
1666211

细菌性阴道炎药物市场规模及预测 2021 - 2031 年，全球及地区份额、趋势及成长机会分析报告范围：按类型、给药途径、剂型、配销通路和地理划分

Bacterial Vaginosis Drug Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Route of Administration, Dosage Form, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 184 Pages | 订单完成后即时交付

价格

根据我们关于「细菌性阴道炎药物市场预测到 2031 年 - 全球分析 - 按类型、给药途径、剂型、配销通路和地区」的新研究，市场预计将从 2024 年的 21.5 亿美元增长到 2031 年的 38.2 亿美元；预计 2024-2031 年期间的复合年增长率为 8.3%。细菌性阴道炎药物市场规模的上升以及对开发新型标靶疗法的日益关注，促进了细菌性阴道炎药物市场规模的不断扩大。然而，高復发率和治疗依从性挑战阻碍了细菌性阴道炎药物市场的成长。此外，人们对微生物组疗法和益生菌的日益关注预计将在未来几年带来新的细菌性阴道炎药物市场趋势。

就收入而言，北美在 2024 年占据市场主导地位。美国是世界上最大的细菌性阴道炎药物市场。在美国，由于细菌性阴道炎药物市场正在经历显着上升、女性健康意识不断增强以及不断努力开发创新治疗方法，细菌性阴道炎药物市场正在经历显着增长。细菌性阴道炎 (BV) 是女性最常见的阴道感染之一，尤其影响育龄女性。根据Medscape在2024年的报告，美国每年约有三分之一的成年女性（约2,200万名女性）受到细菌性阴道炎的影响，有1,000万名女性因阴道分泌物异常而到诊所就诊。它通常与性活动、灌洗和荷尔蒙变化等因素有关；儘管如此，细菌性阴道炎的具体病因仍不确定。治疗细菌性阴道炎 (BV) 的主要治疗选择包括美国食品药物管理局 (FDA) 批准的抗生素，例如甲硝唑和克林霉素。甲硝唑通常以口服和外用形式提供，被认为是治疗细菌性阴道炎的第一线药物。克林霉素通常以口服和外用两种剂型提供。益生菌和噬菌体疗法等较新的药物和製剂也正在出现，有助于恢復天然阴道菌群，从而减少细菌性阴道炎的復发。

美国政府的措施在提高和传播民众对阴道病的认识方面发挥了关键作用。美国国立卫生研究院 (NIH) 资助细菌性阴道炎的病因、治疗和预防的研究。美国国立卫生研究院的努力使我们对微生物群及其在导致细菌性阴道炎中的作用有了更深入的了解，这对于开发更有针对性的治疗方法至关重要。美国疾病管制与预防中心 (CDC) 提供了指南和建议，以改善 BV 的诊断和管理。这些措施有助于标准化护理并确保患者得到最有效的治疗。此外，美国国家儿童健康与人类发展研究所（NICHD，一个联邦机构）和美国国立卫生研究院致力于了解细菌性阴道炎，并教育女性了解其原因和预防措施。 NICHD 资助并进行与 BV 相关的风险以及预防和治疗方法的研究。

细菌性阴道炎药物市场分析

市场参与者的策略性措施为未来提供市场机会

在细菌性阴道炎药物市场运营的公司不断关注策略发展，例如产品批准、合作、资金、协议和新产品发布，这有助于他们提高销售额、扩大地理覆盖范围并增强其满足现有客户群的能力。以下提到了细菌性阴道炎药物市场的主要参与者的一些策略性倡议。

2024年11月，Freya Biosciences获得比尔和梅琳达盖兹基金会1,040万美元的策略性投资，并从现有投资者丹麦出口和投资基金（EIFO）获得140万美元的额外融资。该公司计划利用这些资金开发治疗 BV 的微生物免疫疗法，以解决早产风险以及其他可能影响产妇和新生儿健康的疾病。

2022 年 3 月，Organon 与 Dare Bioscience, Inc. 达成协议，根据该协议，Organon 将授予 XACIATO（克林霉素磷酸盐阴道凝胶，2%）的全球权利。凭藉此产品，XACIATO 获得了美国食品药物管理局 (FDA) 颁发的用于治疗细菌性阴道炎的合格传染病产品 (QIDP) 和快速通道资格。

2022年2月，Lupin Pharmaceuticals Inc.取得FDA核准补充新药申请（sNDA），以增加SOLOSEC（塞克硝唑）在12岁或以上女性病患治疗BV的使用；该批准还涉及对上述年龄组患者的滴虫病进行治疗。

2021年12月，FDA批准了Dare Bioscience, Inc.生产的XACIATO（克林霉素磷酸盐阴道凝胶，2%）用于治疗12岁以上女性的细菌性阴道炎。

2021 年 2 月，Rebiotix（Ferring）和 MyBiotics 合作开发基于活微生物组的治疗方法，用于生殖医学和孕产妇健康。此次合作旨在打造以活微生物为基础的生物疗法药物，用于治疗育龄妇女的细菌性阴道炎，这种疾病可能与流产风险增加以及怀孕及生育併发症有关。

因此，持续的资金、产品发布和批准以及合作预计将为未来几年细菌性阴道炎药物市场的成长创造充足的机会。

细菌性阴道炎药物市场报告細項分析

有助于得出细菌性阴道炎药物市场分析的关键部分是类型、给药途径、剂型和配销通路。

根据类型，细菌性阴道炎药物市场分为处方药和非处方药。 2024 年，处方药市场将占据更大的份额。

根据给药途径，细菌性阴道炎药物市场分为口服、阴道和外用。 2024 年，口服药物将占据市场主导地位。

就剂型而言，细菌性阴道炎药物市场分为丸剂、乳膏、凝胶、溶液/洗剂等。 2024 年，药丸类产品占据市场主导地位。

从配销通路来看，细菌性阴道炎药物市场分为医院药房、网路药房和零售药房。 2024 年，医院药局部门将占据市场主导地位。

细菌性阴道炎药物市场：竞争格局与关键发展

拜耳股份公司、辉瑞公司、赛诺菲公司、Starpharma Holdings Limited、Viatris Inc、Glenmark Pharmaceuticals Ltd、Lupin Ltd、Sun Pharmaceutical Industries Ltd、Organon & Co、Duchesnay Inc.、加拿大是细菌性阴道炎药物市场的主要公司。

《欧洲妇产科和生殖生物学杂誌》、美国国立卫生研究院、Medscape、加拿大政府、联合国2024年世界人口展望、欧盟统计局、欧盟委员会、澳洲政府卫生和老年护理部、世界银行和国际贸易管理局是编写细菌性阴道炎药物市场报告时参考的主要和次要来源。

目录

第 1 章：简介

第 2 章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 发育基数：
    • 数据三角测量：
    • 国家级资料：

第 4 章：细菌性阴道炎药物市场格局

  • 概述
  • PEST分析
  • 发生率：细菌性阴道炎

第 5 章：细菌性阴道炎药物市场 - 主要市场动态

  • 细菌性阴道炎药物市场 - 主要市场动态
  • 市场驱动因素
    • 细菌性阴道炎症率上升
    • 更加重视开发新型标靶疗法
  • 市场限制
    • 高復发率和治疗依从性的挑战
  • 市场机会
    • 市场参与者的策略性倡议
  • 未来趋势
    • 人们对微生物组疗法和益生菌的兴趣日益浓厚
  • 驱动因素和限制因素的影响：

第 6 章：细菌性阴道炎药物市场 - 全球市场分析

  • 细菌性阴道炎药物市场收入，2021-2031 年
  • 细菌性阴道炎药物市场预测分析

第 7 章：细菌性阴道炎药物市场分析 - 按类型

  • 处方药 (Rx)
  • 非处方药 (OTC)

第 8 章：细菌性阴道炎药物市场分析 - 按给药途径

  • 口服
  • 阴道
  • 主题

第 9 章：细菌性阴道炎药物市场分析 - 按剂型

  • 药丸
  • 乳霜
  • 凝胶
  • 溶液或清洗液
  • 其他的

第 10 章：细菌性阴道炎药物市场分析 - 按配销通路

  • 医院药房
  • 网路药局
  • 零售药局

第 11 章：细菌性阴道炎药物市场 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 12 章：产业格局

  • 概述
  • 细菌性阴道炎药物市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 13 章：公司简介

  • Bayer AG
  • Pfizer Inc
  • Sanofi SA
  • Starpharma Holdings Limited
  • Viatris Inc
  • Glenmark Pharmaceuticals Ltd
  • Lupin Ltd
  • Sun Pharmaceutical Industries Ltd
  • Organon & Co
  • Duchesnay Inc., Canada

第 14 章：附录

Product Code: TIPRE00018820

According to our new research study on "Bacterial Vaginosis Drug Market Forecast to 2031 -Global Analysis - by Type, Route of Administration, Dosage Form, and Distribution Channel, and Geography," the market is anticipated to grow from US$ 2.15 billion in 2024 and is projected to reach US$ 3.82 billion by 2031; it is expected to register a CAGR of 8.3% during 2024-2031. Rising prevalence of bacterial vaginosis, and the increased focus on developing novel and targeted therapies are contributing to the growing Bacterial Vaginosis Drug market size. However, the high recurrence rate and treatment adherence challenges hampers the Bacterial Vaginosis Drug market growth. Further, rising inclination toward microbiome therapies and probiotics are expected to bring in new Bacterial Vaginosis Drug market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for bacterial vaginosis drugs in the world. In the US, the bacterial vaginosis drug market is experiencing significant growth due to the increasing prevalence of BV, rising awareness about women's health, and ongoing efforts for the development of innovative treatments. BV is one of the most common vaginal infections in women, particularly affecting those of reproductive age. According to a report by Medscape in 2024, approximately one-third of adult women in the US, i.e., ~22 million females, are affected by BV annually, and 10 million women visit clinics for abnormal vaginal discharge. It is often linked to factors such as sexual activity, douching, and hormonal changes; nonetheless, there is uncertainty around the exact causes of BV. The primary therapeutic options available for treating BV include antibiotics approved by the US Food and Drug Administration (FDA), such as metronidazole and clindamycin. Metronidazole, often available in oral and topical forms, is considered the first-line treatment for BV. Clindamycin is also commonly available in both oral and topical formulations. Newer drugs and formulations, such as probiotics and phage therapy, are also emerging to help restore the natural vaginal flora, thereby reducing the recurrence of BV.

Government initiatives in the US play a key role in creating and spreading awareness about vaginosis in the population. The National Institutes of Health (NIH) funds research into the causes, treatment, and prevention of BV. The NIH's efforts have led to a deeper understanding of the microbiome and its role in causing BV, which is crucial for developing more targeted therapies. Centers for Disease Control and Prevention (CDC) provide guidelines and recommendations to improve the diagnosis and management of BV. These initiatives help standardize care and ensure that patients receive the most effective treatment. Additionally, the National Institute of Child Health and Human Development (NICHD, a federal agency) and NIH are dedicated to understanding BV and educating women about its causes and prevention. NICHD funds and conducts research on the risks associated with BV and methods for its prevention and treatment.

Bacterial Vaginosis Drug Market Analysis

Strategic Initiatives by Market Players to Provide Market Opportunities in Future

Companies operating in the bacterial vaginosis drugs market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and reinforce their capacities to cater to a greater than existing customer base. A few strategic initiatives by key players operating in the bacterial vaginosis drugs market are mentioned below.

In November 2024, Freya Biosciences received US$ 10.4 million in strategic investment from the Bill & Melinda Gates Foundation, with US$ 1.4 million in additional financing from the current investor-Export and Investment Fund of Denmark (EIFO). The company plans to use these funds to develop microbial immunotherapies for the treatment of BV to address the risk of preterm birth along with other indications potentially affecting maternal and newborn health.

In March 2022, Organon and Dare Bioscience, Inc. entered into an agreement whereby Organon will license global rights to XACIATO (clindamycin phosphate vaginal gel, 2%). With this, XACIATO received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US Food and Drug Administration (FDA) for the treatment of bacterial vaginosis.

In February 2022, Lupin Pharmaceuticals Inc. received FDA approval for a supplemental New Drug Application (sNDA) to increase the use of SOLOSEC (secnidazole) for the treatment of BV among female patients aged 12 or older; the approval also entailed the treatment of trichomoniasis among patients from the said age group.

In December 2021, the FDA approved XACIATO (clindamycin phosphate vaginal gel, 2%) manufactured by Dare Bioscience, Inc. for the treatment of bacterial vaginosis in females of age 12 years or more.

In February 2021, Rebiotix (Ferring) and MyBiotics collaborated to develop live microbiome-based therapeutics for applications in reproductive medicine and maternal health. This collaboration aims to create live microbiota-based biotherapeutics for bacterial vaginosis among women of childbearing age, which may be associated with the increased risk of miscarriage and complications in pregnancy and fertility.

Therefore, ongoing funding, product launches and approvals, and collaborations are expected to create ample opportunities for the growth of the bacterial vaginosis drugs market in the coming years.

Bacterial Vaginosis Drug Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Bacterial Vaginosis Drug market analysis are type, route of administration, dosage form, and distribution channel.

Based on type, the bacterial vaginosis drug market is segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment held a larger share of the market in 2024.

In terms of route of administration, the bacterial vaginosis drug market is categorized into oral, vaginal, and topical. The oral segment dominated the market in 2024.

In terms of dosage form, the bacterial vaginosis drug market is categorized into pills, creams, gels, solutions/washes, and others. The pills segment dominated the market in 2024.

In terms of distribution channel, the bacterial vaginosis drug market is categorized into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.

Bacterial Vaginosis Drug Market: Competitive Landscape and Key Developments

Bayer AG, Pfizer Inc, Sanofi SA, Starpharma Holdings Limited, Viatris Inc, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Sun Pharmaceutical Industries Ltd, Organon & Co, Duchesnay Inc., Canada are among the key companies operating in the Bacterial Vaginosis Drug market.

European Journal of Obstetrics & Gynecology and Reproductive Biology, National Institutes of Health, Medscape, Government of Canada, UN World Population Prospects 2024, Eurostat, European Commission, Australian Government's Department of Health and Aged Care, World Bank, and International Trade Administration are among the primary and secondary sources referred to while preparing the Bacterial Vaginosis Drug market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Bacterial Vaginosis Drug Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Incidence Rate: Bacterial Vaginosis

5. Bacterial Vaginosis Drug Market - Key Market Dynamics

  • 5.1 Bacterial Vaginosis Drug Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Bacterial Vaginosis
    • 5.2.2 Increased Focus on Developing Novel and Targeted Therapies
  • 5.3 Market Restraints
    • 5.3.1 High Recurrence Rate and Treatment Adherence Challenges
  • 5.4 Market Opportunities
    • 5.4.1 Strategic Initiatives by Market Players
  • 5.5 Future Trends
    • 5.5.1 Rising Inclination Toward Microbiome Therapies and Probiotics
  • 5.6 Impact of Drivers and Restraints:

6. Bacterial Vaginosis Drug Market - Global Market Analysis

  • 6.1 Bacterial Vaginosis Drug Market Revenue (US$ Million), 2021-2031
  • 6.2 Bacterial Vaginosis Drug Market Forecast Analysis

7. Bacterial Vaginosis Drug Market Analysis - by Type

  • 7.1 Prescription Drugs (Rx)
    • 7.1.1 Overview
    • 7.1.2 Prescription Drugs (Rx): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Over-the-counter Drugs (OTC)
    • 7.2.1 Overview
    • 7.2.2 Over-the-counter Drugs (OTC): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

8. Bacterial Vaginosis Drug Market Analysis - by Route of Administration

  • 8.1 Oral
    • 8.1.1 Overview
    • 8.1.2 Oral: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Vaginal
    • 8.2.1 Overview
    • 8.2.2 Vaginal: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Topical
    • 8.3.1 Overview
    • 8.3.2 Topical: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

9. Bacterial Vaginosis Drug Market Analysis - by Dosage Form

  • 9.1 Pills
    • 9.1.1 Overview
    • 9.1.2 Pills: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Creams
    • 9.2.1 Overview
    • 9.2.2 Creams: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Gel
    • 9.3.1 Overview
    • 9.3.2 Gel: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Solution or Washes
    • 9.4.1 Overview
    • 9.4.2 Solution or Washes: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Others
    • 9.5.1 Overview
    • 9.5.2 Others: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

10. Bacterial Vaginosis Drug Market Analysis - by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Hospital Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Online Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Online Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Retail Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Retail Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

11. Bacterial Vaginosis Drug Market - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Bacterial Vaginosis Drug Market Overview
    • 11.1.2 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.2.1 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
      • 11.1.2.2 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
      • 11.1.2.3 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
      • 11.1.2.4 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.1.3 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.1.3.1 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.1.3.2 United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.2.1 United States: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.1.3.2.2 United States: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.1.3.2.3 United States: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.1.3.2.4 United States: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.1.3.3 Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.3.1 Canada: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.1.3.3.2 Canada: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.1.3.3.3 Canada: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.1.3.3.4 Canada: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.1.3.4 Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.4.1 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.1.3.4.2 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.1.3.4.3 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.1.3.4.4 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Europe Bacterial Vaginosis Drug Market Overview
    • 11.2.2 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.2.1 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
      • 11.2.2.2 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
      • 11.2.2.3 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
      • 11.2.2.4 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.2.3 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.2.3.1 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.2.3.2 Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.2.1 Germany: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.2.2 Germany: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.2.3 Germany: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.2.4 Germany: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.2.3.3 United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.3.1 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.3.2 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.3.3 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.3.4 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.2.3.4 France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.4.1 France: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.4.2 France: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.4.3 France: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.4.4 France: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.2.3.5 Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.5.1 Spain: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.5.2 Spain: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.5.3 Spain: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.5.4 Spain: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.2.3.6 Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.6.1 Italy: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.6.2 Italy: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.6.3 Italy: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.6.4 Italy: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.2.3.7 Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.7.1 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.7.2 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.7.3 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.7.4 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  • 11.3 Asia Pacific
    • 11.3.1 Asia Pacific Bacterial Vaginosis Drug Market Overview
    • 11.3.2 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.2.1 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
      • 11.3.2.2 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
      • 11.3.2.3 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
      • 11.3.2.4 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.3.3 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.3.3.1 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.3.3.2 China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.2.1 China: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.2.2 China: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.2.3 China: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.2.4 China: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.3.3.3 Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.3.1 Japan: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.3.2 Japan: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.3.3 Japan: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.3.4 Japan: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.3.3.4 India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.4.1 India: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.4.2 India: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.4.3 India: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.4.4 India: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.3.3.5 Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.5.1 Australia: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.5.2 Australia: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.5.3 Australia: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.5.4 Australia: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.3.3.6 South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.6.1 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.6.2 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.6.3 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.6.4 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.3.3.7 Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.7.1 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.7.2 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.7.3 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.7.4 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  • 11.4 Middle East and Africa
    • 11.4.1 Middle East and Africa Bacterial Vaginosis Drug Market Overview
    • 11.4.2 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.2.1 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
      • 11.4.2.2 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
      • 11.4.2.3 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
      • 11.4.2.4 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.4.3 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.1 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.2 Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.2.1 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.4.3.2.2 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.4.3.2.3 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.4.3.2.4 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.4.3.3 South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.3.1 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.4.3.3.2 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.4.3.3.3 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.4.3.3.4 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.4.3.4 United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.4.1 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.4.3.4.2 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.4.3.4.3 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.4.3.4.4 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.4.3.5 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.5.1 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.4.3.5.2 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.4.3.5.3 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.4.3.5.4 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  • 11.5 South and Central America
    • 11.5.1 South and Central America Bacterial Vaginosis Drug Market Overview
    • 11.5.2 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.2.1 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
      • 11.5.2.2 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
      • 11.5.2.3 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
      • 11.5.2.4 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.5.3 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.1 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.2 Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.2.1 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.5.3.2.2 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.5.3.2.3 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.5.3.2.4 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.5.3.3 Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.3.1 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.5.3.3.2 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.5.3.3.3 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.5.3.3.4 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.5.3.4 Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.4.1 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.5.3.4.2 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.5.3.4.3 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.5.3.4.4 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in the Bacterial Vaginosis Drug Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Bayer AG
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Pfizer Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Sanofi SA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Starpharma Holdings Limited
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Viatris Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Glenmark Pharmaceuticals Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Lupin Ltd
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Sun Pharmaceutical Industries Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Organon & Co
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Duchesnay Inc., Canada
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms for Bacterial Vaginosis Drug Market

List Of Tables

  • Table 1. Bacterial Vaginosis Drug Market Segmentation
  • Table 2. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Type
  • Table 3. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Route of Administration
  • Table 4. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Dosage Form
  • Table 5. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 7. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 8. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 9. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 11. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 12. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 13. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 14. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 15. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 16. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 17. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 18. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 19. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 20. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 21. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 22. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 23. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 24. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 25. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 26. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 27. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 28. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 29. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 30. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 31. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 32. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 33. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 34. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 35. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 36. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 37. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 38. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 39. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 40. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 41. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 42. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 43. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 44. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 45. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 46. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 47. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 48. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 49. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 50. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 51. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 52. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 53. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 54. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 55. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 56. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 57. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 58. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 59. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 60. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 61. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 62. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 63. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 64. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 65. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 66. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 67. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 68. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 69. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 70. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 71. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 72. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 73. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 74. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 75. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 76. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 77. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 78. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 79. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 80. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 81. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 82. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 83. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 84. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 85. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 86. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 87. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 88. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 89. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 90. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 91. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 92. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 93. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 94. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 95. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 96. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 97. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 98. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 99. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 100. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 101. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 102. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 103. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 104. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 105. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 106. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 107. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 108. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 109. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 110. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 111. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 112. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 113. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 114. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 115. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 116. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 117. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 118. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 119. Recent Organic Growth Strategies in the Bacterial Vaginosis Drug Market
  • Table 120. Recent Inorganic Growth Strategies in the Bacterial Vaginosis Drug Market
  • Table 121. Glossary of Terms

List Of Figures

  • Figure 1. Bacterial Vaginosis Drug Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Bacterial Vaginosis Drug Market Revenue (US$ Million), 2021-2031
  • Figure 5. Bacterial Vaginosis Drug Market Share (%) - by Type (2024 and 2031)
  • Figure 6. Prescription Drugs (Rx): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Over-the-counter Drugs (OTC): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Bacterial Vaginosis Drug Market Share (%) - by Route of Administration (2024 and 2031)
  • Figure 9. Oral: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Vaginal: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Topical: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Bacterial Vaginosis Drug Market Share (%) - by Dosage Form (2024 and 2031)
  • Figure 13. Pills: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Creams: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Gel: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Solution or Washes: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Others: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Bacterial Vaginosis Drug Market Share (%) - by Distribution Channel (2024 and 2031)
  • Figure 19. Hospital Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Online Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Retail Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 23. North America: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 24. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 25. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 26. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 27. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 28. Europe: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 29. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. Asia Pacific: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 37. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 45. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 48. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 50. South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 51. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. Growth Strategies in the Bacterial Vaginosis Drug Market